Ketamine
As of the edition of 20 October 2026, Ketamine is a small molecule: marketed, first approved in 1968 (ES); acts on GRIN1, GRIN2A and GRIN2B and 4 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2022
- Kind
- Small molecule
- Brand name
- Ketalar
- First approved
- 1 December 1968 (ES)
- Approvals on record
- 7 in 5 regions
- Holder of the most recent approval
- Baxter Healthcare; 4 holders in all
- Registered trials
- 779, 131 stopped early
- Disease areas
- Mental health; Nervous system; Cancer; Injuries; Chemically induced; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
10 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product10 company-target rows are on route B because of Ketamine.
See the 10 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| GRIN2D | Glutamate receptor ionotropic, NMDA 2D | O15399 |
| GRIN3B | Glutamate receptor ionotropic, NMDA 3B | O60391 |
| GRIN1 | Glutamate receptor ionotropic, NMDA 1 | Q05586 |
| GRIN2A | Glutamate receptor ionotropic, NMDA 2A | Q12879 |
| GRIN2B | Glutamate receptor ionotropic, NMDA 2B | Q13224 |
| GRIN2C | Glutamate receptor ionotropic, NMDA 2C | Q14957 |
| GRIN3A | Glutamate receptor ionotropic, NMDA 3A | Q8TCU5 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 171 | 97 | 25 | 18 |
| Phase 1 | 118 | 60 | 18 | 24 |
| Phase 2 | 171 | 82 | 39 | 32 |
| Phase 3 | 129 | 48 | 31 | 25 |
| Phase 4 | 190 | 101 | 20 | 32 |
| All trials | 779 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Applicant and Lead sponsor of trials | 1969 to now |
| Baxter Healthcare | Applicant | 2022 to now |
| Ph Health | Acquired holder | 2025 to now |